Despite Uptake Barriers, Real-World Biosimilar Data Demonstrate Safety, Efficacy, Cost-Effectiveness
AJMC,
Biosimilars were a recurring subject at The Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.
Rituximab Reference vs Biosimilar Utilization for Oncology vs Nononcology Indications
AJMC,
ABSTRACT Objectives: Limited data exist on the adoption of rituximab biosimilars vs the reference product by indication.
New US Legislation Creates Momentum For Biosimilars
Life Science Leader,
By Stacie L. Ropka, Ph.D., Ted Mathias, and Ramya Auroprem; Axinn, Veltrop
Consider Adopting Biosimilars Into Clinical Practice
Pharmacy Times,
Andrew J. Donnelly, PharmD, MBA, FASHP; and Jamie Paek, PharmD The number of biosimilar agents available for use in clinical…